CRO Quintiles says that it has filed a registration statement with the US. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of an undisclosed number of shares of common stock. The company says that it plans to use the proceeds to pay down debt and “for general corporate purposes.” Quintiles previously went public in 1994, then went private again in 2003.
In addition to offering respiratory clinical study services, Quintiles is also involved with the commercialization of several OINDPs. In 2012, Quintiles entered into a deal with Almirall to promote Almirall’s respiratory drugs, including the Eklira Genuair DPI, in the UK. It is also partnered with Pharmaxis to market Bronchitol inhaled mannitol.
Read the Quintiles press release.
